Illumina, Inc. (NASDAQ:ILMN) Stock Holdings Lifted by Kestra Advisory Services LLC

Kestra Advisory Services LLC raised its stake in Illumina, Inc. (NASDAQ:ILMNGet Rating) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,130 shares of the life sciences company’s stock after buying an additional 298 shares during the period. Kestra Advisory Services LLC’s holdings in Illumina were worth $1,742,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Prudential PLC increased its holdings in shares of Illumina by 0.8% in the second quarter. Prudential PLC now owns 6,500 shares of the life sciences company’s stock valued at $1,198,000 after buying an additional 49 shares in the last quarter. Eukles Asset Management raised its stake in Illumina by 1.0% during the 2nd quarter. Eukles Asset Management now owns 4,887 shares of the life sciences company’s stock valued at $901,000 after purchasing an additional 50 shares during the period. Corient Capital Partners LLC raised its stake in Illumina by 2.7% during the 2nd quarter. Corient Capital Partners LLC now owns 1,911 shares of the life sciences company’s stock valued at $352,000 after purchasing an additional 50 shares during the period. Financial Consulate Inc. raised its stake in Illumina by 3.5% during the 3rd quarter. Financial Consulate Inc. now owns 1,617 shares of the life sciences company’s stock valued at $309,000 after purchasing an additional 54 shares during the period. Finally, Kidder Stephen W raised its stake in Illumina by 0.5% during the 2nd quarter. Kidder Stephen W now owns 11,502 shares of the life sciences company’s stock valued at $2,121,000 after purchasing an additional 57 shares during the period. Institutional investors own 87.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on ILMN. Royal Bank of Canada assumed coverage on shares of Illumina in a research note on Tuesday, December 6th. They set an “outperform” rating and a $282.00 target price on the stock. TheStreet cut shares of Illumina from a “c-” rating to a “d” rating in a report on Thursday, November 3rd. Citigroup cut shares of Illumina from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $200.00 to $180.00 in a report on Monday, December 12th. Morgan Stanley decreased their price target on shares of Illumina from $240.00 to $225.00 and set an “equal weight” rating for the company in a report on Monday, November 7th. Finally, Barclays upped their price objective on shares of Illumina from $130.00 to $175.00 and gave the company an “underweight” rating in a research report on Friday, September 30th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $252.84.

Illumina Price Performance

ILMN opened at $204.39 on Monday. Illumina, Inc. has a one year low of $173.45 and a one year high of $383.98. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.93 and a quick ratio of 0.72. The company’s 50 day simple moving average is $207.79 and its 200-day simple moving average is $207.68. The stock has a market capitalization of $32.15 billion, a P/E ratio of -7.74 and a beta of 1.14.

Illumina (NASDAQ:ILMNGet Rating) last posted its earnings results on Thursday, November 3rd. The life sciences company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.29 by $0.05. Illumina had a negative net margin of 88.40% and a positive return on equity of 4.36%. The company had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.10 billion. Sell-side analysts anticipate that Illumina, Inc. will post 2.23 earnings per share for the current fiscal year.

Insider Activity

In other Illumina news, SVP Susan H. Tousi sold 500 shares of the business’s stock in a transaction dated Tuesday, December 6th. The shares were sold at an average price of $212.63, for a total value of $106,315.00. Following the completion of the sale, the senior vice president now owns 39,162 shares of the company’s stock, valued at approximately $8,327,016.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Illumina news, SVP Aimee L. Hoyt sold 871 shares of the company’s stock in a transaction on Monday, January 9th. The shares were sold at an average price of $205.57, for a total transaction of $179,051.47. Following the transaction, the senior vice president now owns 2,796 shares in the company, valued at $574,773.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Susan H. Tousi sold 500 shares of the company’s stock in a transaction on Tuesday, December 6th. The stock was sold at an average price of $212.63, for a total transaction of $106,315.00. Following the transaction, the senior vice president now owns 39,162 shares in the company, valued at approximately $8,327,016.06. The disclosure for this sale can be found here. Insiders sold a total of 2,371 shares of company stock valued at $499,481 in the last quarter. Company insiders own 0.13% of the company’s stock.

About Illumina

(Get Rating)

Illumina, Inc provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments.

See Also

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNGet Rating).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.